Hanchorbio’s HCB-101 cleared by FDA to enter clinic for advanced solid tumors and NHL
April 18, 2023
Hanchorbio Inc. has received IND clearance by the FDA to initiate a clinical trial of HCB-101, for the treatment of patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma (NHL).
